Industry's neglect of prescribing information for children

Peterson, Bob; Hébert, Paul C.; MacDonald, Noni; Rosenfield, Daniel; Stanbrook, Matthew B.; Flegel, Ken
June 2011
CMAJ: Canadian Medical Association Journal;6/14/2011, Vol. 183 Issue 9, p994
Academic Journal
The authors reflect on the failure of the pharmaceutical industry to submit evidence supporting safe pediatric doses and dosing intervals to Health Canada. The authors state that according to the "Compendium of Pharmaceuticals and Specialties" (CPS), there is insufficient evidence to support the use of Celebrex in juvenile idiopathic arthritis. They suggest that Canadian children can be protected by asking politicians to enact legislation similar to the U.S. Pediatric Research Equity Act.


Related Articles

  • Developing standards of care for patients with juvenile idiopathic arthritis. Wallace, Carol A. // Rheumatology;Jul2010, Vol. 49 Issue 7, p1213 

    The author discusses an article about the British Society for Paediatric and Adolescent Rheumatology's (BSPAR) Standards of Care for Children and Young People with Juvenile Idiopathic Arthritis, by Karen Davies and colleagues, published within the issue. She claims that the BSPAR guidelines...

  • Efficacy of methylprednisolone pulse therapy in children with rheumatoid arthritis. Aghighi, Yahya; Attarod, Lida; Javanmard, Maryam // Clinical Rheumatology;Nov2008, Vol. 27 Issue 11, p1371 

    Pulse therapy is one of the most well-known methods used in the treatment of juvenile rheumatoid arthritis. This study assessed the outcome of methylprednisolone pulse therapy, its rate of efficacy, and its associated complications in patients with juvenile rheumatoid arthritis (JRA). This...

  • Eye on Washington. Asch-Goodkin, Judith // Contemporary Pediatrics;Feb2007, Vol. 24 Issue 2, p16 

    The article presents health-related news briefs in the U.S. Congress voted 253 to 174 to broaden federal support for embryonic stem cell research. The Centers for Disease Control and Prevention (CDC) is warning clinicians and parents of the side effects of over-the-counter cough and cold...

  • Abbott: another promising year for Humira.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p20 

    The article reports that Abbott Laboratories Inc. seeks an approval for the marketing of Humira as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and Europe. Other than the approval of Humira as a therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis,...

  • Health Canada won't guarantee imports.  // Drug Store News;5/19/2003, Vol. 25 Issue 7, p1 

    Reports that Health Canada will not guarantee drugs exported to the United States.

  • Pediatric Rheumatology.  // Current Medical Literature: Rheumatology;2009, Vol. 28 Issue 2, p44 

    The article presents medical studies on pediatric rheumatology published in medical journals in 2008 and 2009. A study by F. Falcini and colleagues examined the effectiveness and side effects of mycophenolate mofetil when used to treat children with systemic lupus erythematosus. Another study...

  • Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists. Armbrust, Wineke; Kaak, Jolanda G.; Bouma, Jelte; Lelieveld, Otto T. H. M.; Wulffraat, Nico M.; Sauer, Pieter J. J.; van Sonderen, Eric // Pediatric Rheumatology;2013, Vol. 11 Issue 1, p1 

    Background Self assessment of arthritis is important for recognition of disease activity and early initiation of therapy. Proper interpretation of physical symptoms is necessary for this. The purpose was to investigate the assessment by patients and parents of disease activity in juvenile...

  • PAEDIATRICS. Smith, Carol // Journal of Pharmacy Practice & Research;2009, Vol. 39 Issue 4, p324 

    The article presents abstracts on pediatric research topics which include the use of propranolol for infantile hemangiomas, the management of juvenile idiopathic arthritis and the efficacy of rectal paraldehyde in the management of tonic-clonic seizures in children.

  • Independent confirmation of juvenile idiopathic arthritis genetic risk loci previously identified by immunochip array analysis. Chiaroni-Clarke, Rachel C.; Munro, Jane E.; Chavez, Raul A.; Pezic, Angela; Allen, Roger C.; Akikusa, Jonathan D.; Piper, Susan E.; Saffery, Richard; Ponsonby, Anne-Louise; Ellis, Justine A. // Pediatric Rheumatology;2014, Vol. 12 Issue 1, p30 

    Background Our understanding of the genetic factors underlying juvenile idiopathic arthritis (JIA) is growing, but remains incomplete. Recently, a number of novel genetic loci were reported to be associated with JIA at (or near) genome-wide significance in a large case-control discovery sample...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics